Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9331998 | 0.83 | TPMT (0.48) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL21614387 | 0.83 | ALDH1A1 (0.42) | HSD17B10TSHRHPGDTPMTCASP1 | |
| SCHEMBL23972597 | 0.83 | HSD17B10 (0.43) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL9331965 | 0.82 | HPGD (0.56) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL9331976 | 0.82 | HSD17B10 (0.52) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL31213023 | 0.82 | HSD17B10 (0.52) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL21614379 | 0.80 | TPMT (0.43) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL14811454 | 0.78 | TPMT (0.42) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL9938269 | 0.78 | TPMT (0.42) | HSD17B10TSHRHPGDMAPK1TPMT | |
| SCHEMBL481060 | 0.78 | CYP3A4 (0.50) | HSD17B10TSHRHPGDMAPK1TPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | UNIVERSITE DE CAEN NORMANDIE (FR) | 2021-11-04 | — | — | US | disclosed |
| WO-2020007882-A1 | M-GUAIACOL DERIVATIVES, PREPARATION THEREOF, AND USES THEREOF | UNIVERSITE DE CAEN NORMANDIE (FR) | 2020-01-09 | — | — | WO | disclosed |
| EP-0850246-B1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-11-14 | — | — | EP | disclosed |
| EP-0850246-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| US-5705492-A | ESTERIFICATION OF PYRIMIDINE NUCLEOSIDE | HOFFMANN-LA ROCHE INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997003082-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | MPG, MGLL, GANC | HSD17B10 1613/4885TSHR 4544/4885HPGD 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.